Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Privium Fund Management B.V.

Key Points

• Privium Fund Management increased its Alnylam stake by 81.2% in the third quarter, bringing its holdings to 20,607 shares valued at about $5.1 million. Institutional investors collectively own nearly 93% of the stock.
• Analysts have cut price targets, including Goldman Sachs’ reduction from $536 to $320, but the consensus rating remains “Moderate Buy” with a $305.86 price target.
• Alnylam shares recently traded at $155.94, near their 12-month low. Its latest quarterly revenue was $1.46 billion, up 16.7% year over year and above analysts’ expectations.

Privium Fund Management B.V. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 81.2% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 20,607 shares of the biopharmaceutical company's stock after purchasing an additional 9,235 shares during the period. Alnylam Pharmaceuticals comprises approximately 1.0% of Privium Fund Management B.V.'s portfolio, making the stock its 23rd biggest holding. Privium Fund Management B.V.'s holdings in Alnylam Pharmaceuticals were worth $5,085,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. SCS Capital Management LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at about $34,784,000. WINTON GROUP Ltd purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $2,372,000. Silvant Capital Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $5,456,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $50,773,000. Finally, Wealthfront Advisers LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $2,876,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ALNY has been the subject of a number of recent analyst reports. The Goldman Sachs Group decreased their target price on Alnylam Pharmaceuticals from $536.00 to $320.00 and set a "buy" rating for the company in a report on Friday, October 30th. HC Wainwright reiterated a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 28th. Citigroup reduced their price objective on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a "buy" rating on the stock in a research report on Wednesday, October 14th. Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $345.00 to $280.00 and set an "outperform" rating for the company in a report on Friday, October 30th. Finally, Raymond James Financial lowered shares of Alnylam Pharmaceuticals from a "strong-buy" rating to an "outperform" rating and decreased their price objective for the stock from $420.00 to $315.00 in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $305.86.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the company's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the sale, the executive vice president owned 12,807 shares in the company, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Down 0.5%

Shares of ALNY traded down $0.72 on Friday, reaching $155.94. The stock had a trading volume of 2,829,678 shares, compared to its average volume of 2,343,089. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. Alnylam Pharmaceuticals, Inc. has a 12-month low of $154.30 and a 12-month high of $479.79. The firm has a market capitalization of $20.89 billion, a price-to-earnings ratio of 8.10 and a beta of 0.42. The company has a 50-day simple moving average of $228.57 and a 200-day simple moving average of $281.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.66 by $14.60. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The firm's quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.90 earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach.

Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.